NX-1607
NX-1607 (Compound 23) is an inhibitor of Cbl-b, an E3 enzyme in the ubiquitin-proteasome pathway, with an IC50 value of less than 1 nM. NX-1607 can be used in cancer research[1].
Product Specifications
CAS Number
[2573775-59-2]
Product Name Alternative
Cbl-b-IN-3
UNSPSC
12352005
Target
E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nx-1607.html
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CN1C([C@@]2(C3=CC(N4CC5=C(C(F)(F)F)C=C(CN6C[C@H](CCC6)C)C=C5C4=O)=CC=C3)C[C@H](C2)C)=NN=C1
Molecular Formula
C30H34F3N5O
Molecular Weight
537.62
References & Citations
[1]Arthur T. Sands, et al. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof. WO2020264398A1.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CP2AD (Cytochrome P450 2A7, Cytochrome P450 Family 2 Subfamily A Member 7)
